Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE.
DUETACT vs ROSIGLITAZONE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Rosiglitazone is a thiazolidinedione that acts as a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ). Activation of PPARγ increases insulin sensitivity in adipose tissue, skeletal muscle, and liver, leading to reduced hepatic gluconeogenesis and increased glucose uptake.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
4 mg orally once daily; may increase to 8 mg once daily after 12 weeks if inadequate glycemic response.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Terminal elimination half-life is 3-4 hours; clinically relevant as dosing is twice daily to maintain steady-state concentrations.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Primarily hepatic metabolism via CYP2C8, with less than 1% excreted unchanged in urine. Fecal excretion of metabolites accounts for approximately 64% and renal excretion for 23% of the dose.
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione